In recent years, biological agents, such as tumor necrosis factor (TNF-α) or IL-17 antagonists, have been proposed in patients with specific characteristics associated with a higher likelihood of response: elevated C-reactive protein levels (CRP), the presence of inflammation on MRI-SIJ, and the presence of radiographic sacroiliitis. This evidence concerns the gene TNF and Sacroiliac arthritis.